Cargando...
Characterization of newly established Pralatrexate-resistant cell lines and the mechanisms of resistance
BACKGROUND: Pralatrexate (PDX) is a novel antifolate approved for the treatment of patients with relapsed/refractory peripheral T-cell lymphoma, but some patients exhibit intrinsic resistance or develop acquired resistance. Here, we evaluated the mechanisms underlying acquired resistance to PDX and...
Gardado en:
| Publicado en: | BMC Cancer |
|---|---|
| Main Authors: | , , , , , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado: |
BioMed Central
2021
|
| Assuntos: | |
| Acceso en liña: | https://ncbi.nlm.nih.gov/pmc/articles/PMC8325835/ https://ncbi.nlm.nih.gov/pubmed/34332580 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s12885-021-08607-9 |
| Tags: |
Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!
|